Ministers restrict dispensing of menopause drug Utrogestan after supply issues
Pharmacists will be able to dispense a maximum of two months’ supply per prescription in a bid to allow patients continued access.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Ministers have moved to restrict the dispensing of a medicine used to treat the symptoms of menopause due to shortages being experienced in Britain.
The UK Government issued a serious shortage protocol (SSP) for Utrogestan 100mg capsules on Friday.
It means pharmacists will be able to dispense a maximum of two months’ supply per prescription in a bid to ensure women who use the hormone replacement therapy (HRT) can continue to access treatment.
According to the Department of Health and Social Care (DHSC), Utrogestan is expected to be in intermittent supply until late this year.
Today’s decisive action will mean more women will be able to access this medicine
Officials said manufacturer Besins was increasing supply but was currently struggling to meet rising demand.
Women’s minister Maria Caulfield said: “Today’s decisive action will mean more women will be able to access this medicine, and I want to reassure women that the vast majority of HRT products are in good supply.
“The overall supply of HRT products has improved considerably over the last year and I am encouraged by how the industry is responding to the growth in demand and our continued calls for action to boost supply to meet it.
“We continue working to help ensure continuity of supply – which is a key part of increasing support for menopausal and pre-menopausal women and improving their quality of life.”
The DHSC said a serious shortage protocol was a standard procedure, used frequently to manage temporary and potential medicine supply issues.
Since April last year, 22 SSPs have been made for HRT products but the department said only two remain in place – one relating to Friday’s Utrogestan order and a second for Progynova 100 microgram patches.
An official said some HRT medicines had been added to the list of products that cannot be exported from, or hoarded in, the UK in a bid to ensure adequate supply remains available to patients.